İnovasyon ve fikri mülkiyet · 22.05.19961 dk okuma
Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
Yerel otomatik çeviri · Kaynağın orijinal dili
Özet
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.